Open-label extension
Showing 1 - 25 of >10,000
Safety Issues Trial (Nicotinamide Riboside)
Recruiting
- Safety Issues
- Nicotinamide Riboside
-
Bergen, Vestland, NorwayHaukeland University Hospital
Nov 25, 2022
Becker Muscular Dystrophy Trial in Atlanta (EDG-5506)
Enrolling by invitation
- Becker Muscular Dystrophy
-
Atlanta, GeorgiaRare Disease Research
Sep 27, 2023
Alpha 1-Antitrypsin Deficiency, Emphysema Trial (INBRX-101)
Not yet recruiting
- Alpha 1-Antitrypsin Deficiency
- Emphysema
- (no location specified)
May 31, 2023
Thyroid Eye Disease, TED Trial in Shanghai (IBI311)
Recruiting
- Thyroid Eye Disease, TED
-
Shanghai, Shanghai, ChinaNinth People's Hospital Affiliated to Shanghai Jiao Tong Univers
Nov 9, 2023
Amyotrophic Lateral Sclerosis Trial in Barcelona (FAB122)
Recruiting
- Amyotrophic Lateral Sclerosis
-
Barcelona, SpainHospital Universitari de Bellvitge
May 10, 2023
Autism Spectrum Disorder Trial in Staten Island (ML-004 (IR)/(ER) tablet)
Recruiting
- Autism Spectrum Disorder
- ML-004 (IR)/(ER) tablet
-
Staten Island, New YorkRichmond Behavioral Associates
Jun 1, 2023
Psychosis Associated With Alzheimer's Disease Trial in Lafayette (KarXT)
Enrolling by invitation
- Psychosis Associated With Alzheimer's Disease
-
Lafayette, CaliforniaClinical Trial Site
Jul 31, 2023
Secondary Hyperparathyroidism Trial (PLS240, Placebo, Open-Label Extension PLS240)
Not yet recruiting
- Secondary Hyperparathyroidism
- PLS240
- +2 more
- (no location specified)
Apr 17, 2023
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome Trial in Glenview (Efgartigimod)
Recruiting
- Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
-
Glenview, IllinoisNorth Shore University HealthSystem
Jun 22, 2023
Secondary Hyperparathyroidism, End Stage Kidney Disease Trial (PLS240, Placebo, Open-Label Extension PLS240)
Not yet recruiting
- Secondary Hyperparathyroidism
- End Stage Kidney Disease
- PLS240
- +2 more
- (no location specified)
Apr 18, 2023
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic Trial in New Orleans (HZN-825)
Recruiting
- Diffuse Cutaneous Systemic Sclerosis
- Sclerosis, Systemic
-
New Orleans, LouisianaDelRicht Clinical Research, LLC
Nov 15, 2022
Myasthenia Gravis, Generalized Trial in China (Tocilizumab Injection)
Enrolling by invitation
- Myasthenia Gravis, Generalized
- Tocilizumab Injection
-
Beijing, Beijing, China
- +5 more
Jan 27, 2023
Fragile X Syndrome Trial (Zatolmilast/ BPN14770)
Not yet recruiting
- Fragile X Syndrome
- Zatolmilast/ BPN14770
- (no location specified)
May 5, 2022
Alzheimer Trial in East Providence, Austin (Simufilam)
Enrolling by invitation
- Alzheimer Disease
-
East Providence, Rhode Island
- +1 more
Jan 5, 2023
SARS-CoV-2 Trial in Singapore (ARCT-021)
Terminated
- SARS-CoV-2
- ARCT-021
-
Singapore, SingaporeSingHealth Investigational Medicine Unit (IMU), Singapore Genera
Jul 7, 2022
Amyotrophic Lateral Sclerosis Trial in Fredericton, Montréal (Reldesemtiv)
Recruiting
- Amyotrophic Lateral Sclerosis
-
Fredericton, New Brunswick, Canada
- +1 more
Aug 9, 2022
Amyloidosis; Systemic Trial in Woolloongabba, Box Hill (AT02)
Not yet recruiting
- Amyloidosis; Systemic
-
Woolloongabba, Queensland, Australia
- +1 more
Jul 11, 2023
Hereditary Angioedema Trial (KVD900 600 mg)
Not yet recruiting
- Hereditary Angioedema
- KVD900 600 mg
- (no location specified)
Aug 17, 2022
Sickle Cell Disease Trial (open-label GBT021601)
Not yet recruiting
- Sickle Cell Disease
- open-label GBT021601
- (no location specified)
Nov 21, 2022
Depressive Disorder Trial in Nashville (Transdermal Nicotine patch)
Not yet recruiting
- Depressive Disorder
- Transdermal Nicotine patch
-
Nashville, TennesseeVanderbilt Psychiatric Hospital
Feb 28, 2023